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This article provides an analysis of the in vitro effect of qnrA1, qnrB1, and qnrS1 genes, combined with
quinolone-resistant Ser83Leu substitutions in GyrA and/or Ser80Arg in ParC, on fluoroquinolone (FQ)
resistance in isogenic Escherichia coli strains. The association of Ser83Leu substitution in GyrA, Ser80Arg
substitution in ParC, and qnr gene expression increased the MIC of ciprofloxacin to 2 g/ml. qnr genes present
in E. coli that harbored a Ser83Leu substitution in GyrA increased mutant prevention concentration (MPC)
values to 8 to 32 g/ml. qnr gene expression in E. coli may play an important role in selecting for one-step
FQ-resistant mutants.
Fluoroquinolone (FQ) resistance occurs mainly as a result
of mutations in chromosomal genes encoding quinolone tar-
gets, DNA gyrase and topoisomerase IV (5). More recently,
plasmid-mediated mechanisms, such as those mediated by
the qnr, aac(6)-Ib-cr, and qepA genes, have been reported
(11, 18). In the absence of other mechanisms, the presence
of any qnr gene increased the MIC of FQ between 4- and
128-fold, although MIC values remained below CLSI break-
points (9, 18).
It has been suggested that Qnr proteins facilitate the selec-
tion of higher-level quinolone-resistant mutants. In spite of
this, the therapeutic relevance of the acquisition of qnr genes
on FQ bactericidal activity remains unclear (10, 13, 16). Since
spontaneous bacterial mutants usually arise at a low frequency
of 106 to 108, the prevention of mutant bacterial popula-
tions may help to restrict the development of antimicrobial
resistance. To avoid selecting for resistance, drug concentra-
tions should be kept above the mutant prevention concentra-
tion (MPC) (4, 20). In vivo studies have shown that the pres-
ence of qnr genes in association with additional quinolone
resistance mechanisms might be relevant in the activity of these
antimicrobial agents (1, 15).
In a recent study (12), the combined effect of topoisomerase
mutations on FQ resistance in isogenic Escherichia coli strains
showed that at least three mutations—two of which had to be
in gyrA—were necessary to exceed CLSI resistance break-
points. Plasmid-mediated quinolone resistance (PMQR) genes
confer low levels of quinolone resistance, and their precise
effect on selecting for quinolone resistance in association
with other mechanisms is not well known. In addition, re-
cent studies have shown that the qnrA gene increased the
MPC against FQ (16). The aim of this study was to evaluate
the effect of qnrA, qnrB, and qnrS genes on the development
of quinolone resistance in wild-type E. coli strains compared
to isogenic E. coli strains harboring mutated gyrA and/or
parC genes.
Ser83Leu and Ser80Arg mutations, located in GyrA and
ParC, respectively, were obtained by gene replacement, as de-
scribed by Posfai et al. (14). The qnr genes carried on the
pBK-CMV cloning vector were transformed by electropora-
tion into E. coli ATCC 25922 and its isogenic mutant strains E.
coli ATCC 25922-S83L, E. coli ATCC 25922-S80R, and E. coli
ATCC 25922-S83L-S80R (Table 1). The primers used to ob-
tain the different isogenic strains are indicated in Table 2.
Susceptibility tests were performed in duplicate for each
bacterial strain by the broth microdilution method according to
CLSI reference methods (2). The presence of any qnr gene
increased MIC levels in all E. coli genotypes. The ciprofloxacin
(CIP) MIC for E. coli ATCC 25922 harboring any qnr gene was
0.125 g/ml, which is more than 62-fold higher than that for
the empty wild-type strain (Table 1). The expression of qnr
genes in the E. coli ATCC-Ser83Leu strain gave a less marked
increase, with CIP MICs of 0.5, 0.5, and 1 g/ml, meaning 4-,
4-, and 8-fold increases in expression for qnrA1, qnrB1, and
qnrS1, respectively. The Ser80Arg substitution in ParC played
a secondary role in FQ resistance (Table 1), as previously
described (7, 12). In E. coli ATCC-Ser83Leu-Ser80Arg, the
presence and expression of qnrA1 or qnrS1 genes increased the
CIP MIC to 2 g/ml (or intermediate susceptibility according
to CLSI guidelines) (Table 1) (2). Isogenic strains containing
the qnrB1 gene were always susceptible to FQ according to
CLSI breakpoints, including the double-topoisomerase mutant
(Table 1). qnrB1 seems to be slightly less efficient than qnrA1
and qnrS1 in terms of MIC values. Minimal bactericidal con-
centrations (MBCs) were similar to the corresponding MIC
values.
MPC was determined as described previously by Marcusson
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et al. (8, 16). The presence of qnr genes increased MPC values
of FQ in all E. coli genotypes. The MPC values of CIP in the
wild-type E. coli ATCC 25922 strain coding for Qnr proteins as
the only quinolone resistance mechanism increased 8-, 2-, and
4-fold for qnrA1, qnrB1, and qnrS1, respectively, compared to
E. coli ATCC 25922 (Table 3). A similar increase was observed
for the other quinolones. The presence of a single Ser83Leu
mutation in the gyrA gene raised MPC values 2- to 4-fold,
compared to those for wild-type E. coli ATCC 25922. The
additional presence of qnr genes in E. coli ATCC-Ser83Leu
increased MPC values to 8 to 32 g/ml, depending on the FQ
(Table 3). E. coli ATCC-Ser83Leu-Ser80Arg MPC values
ranged from 4 to 32 g/ml. E. coli ATCC-Ser83Leu-Ser80Arg
expressing qnr genes showed MPC values ranging from 32 to
128 g/ml (except for qnrB1, for which values ranged from 8 to
32 g/ml), well in excess of the breakpoint concentrations of
CLSI guidelines (data not shown). The effect of qnr genes on
MPC was similar to the presence of a Ser83Leu substitution in
GyrA as the single quinolone resistance mechanism. MPC
concentrations were clearly higher than the maximum serum
concentrations obtained when using drugs in antimicrobial
therapy for E. coli ATCC 25922-Ser83Leu expressing qnr genes
(6, 19). The presence of quinolone resistance mechanisms pro-
duced a reduction in the mutant selection window (MSW). It is
therefore difficult to predict MPC from the MIC values, and on
this basis, the MPC will vary according to FQ and the specific
resistance mechanism involved (Table 3).
Mutants were recovered from the plated concentrations
closest to the MPC value at a very low frequency. The quino-
lone resistance-determining region (QRDR) of target genes
gyrA and parC was analyzed. All of the characterized mutants
of the E. coli ATCC 25922 strain had just a Ser83Leu substi-
tution in the QRDR of gyrA, supporting the view that this is the
most frequent modification in E. coli. On the other hand, most
colonies of the E. coli ATCC-Ser83Leu strain selected in the
MSW showed additional modifications in the QRDR of the
parC gene (Gly78Asp or Ser80Ile substitutions), also previ-
ously associated with quinolone resistance. Clinical FQ resis-
tance according to CLSI guidelines (2) (MIC of 4 g/ml for
CIP) was observed for some of these mutants (Table 3). The
PMQR might enable mutant bacteria with low levels of FQ
resistance to survive long enough for them to grow and emerge
during FQ treatment. The detection of mutations in type II
topoisomerase genes reflects the ability of this mechanism
to select for mutants with higher quinolone resistance. In
vivo selection of FQ-resistant Enterobacteriaceae expressing
qnr genes has been reported (3, 13). With respect to bacte-
rial survival, although some bacteria did survive the MPC
for a 96-h extended period, no quinolone-resistant mutants
were selected, these being a persistent phenotype and indi-
cating that the MPC parameter was working as specified
(Table 3) (8).
Killing-curve assays showed a selective advantage for sur-
vival at 1 g/ml of CIP in strains expressing qnr genes, both
with and without the Ser83Leu substitution in GyrA in E. coli
(Fig. 1). This CIP concentration defines the limit for establish-
ing susceptibility or intermediate susceptibility (according to
CLSI guidelines) in Enterobacteriaceae (2). CIP at 1 g/ml in
the isogenic wild-type E. coli strain ATCC 25922 (with or
without qnr gene expression [Fig. 1A]) caused a marked re-
TABLE 1. Bacterial strains and fluoroquinolone MIC and MBCs
E. coli strain/







MIC (g/ml)c MBC (g/ml)
CIP LVX MXF NFX CIP LVX MXF NFX
ATCC 25922 Wild type None S 0.002 0.008 0.008 0.015 0.015 0.03 0.015 0.03
ATCC/qnrA Wild type pBK-QnrA1 S 0.125 0.5 0.25 0.5 0.125 0.5 0.5 1
ATCC/qnrB Wild type pBK-QnrB1 S 0.125 0.125 0.25 0.25 0.125 0.25 1 0.5
ATCC/qnrS Wild type pBK-QnrS1 S 0.125 0.5 0.25 0.5 0.25 0.5 0.25 1
ATCC 25922-S83L GyrA Ser83Leu None S 0.125 0.125 0.06 0.125 0.125 0.25 0.125 0.5
ATCC-S83L/qnrA GyrA Ser83Leu pBK-QnrA1 S 0.5 0.5 0.5 2 0.5 0.5 0.5 2
ATCC-S83L/qnrB GyrA Ser83Leu pBK-QnrB1 S 0.5 0.25 0.5 1 0.5 0.5 0.5 1
ATCC-S83L/qnrS GyrA Ser83Leu pBK-QnrS1 S 1 1 1 2 1 2 2 4
ATCC 25922-S80R ParC Ser80Arg None S 0.004 0.008 0.008 0.03 0.004 0.008 0.008 0.03
ATCC-S80R/qnrA ParC Ser80Arg pBK-QnrA1 S 0.25 0.25 0.5 0.5 0.25 0.5 0.5 2
ATCC-S80R/qnrB ParC Ser80Arg pBK-QnrB1 S 0.125 0.25 0.5 0.5 0.25 0.5 0.5 0.5
ATCC-S80R/qnrS ParC Ser80Arg pBK-QnrS1 S 0.125 0.25 0.25 0.5 0.25 0.25 0.5 0.5
ATCC 25922-S83L-S80R GyrA Ser83Leu,
ParC Ser80Arg
None S 0.25 0.25 0.25 2 2 0.25 0.25 2
ATCC-S83L-S80R/qnrA GyrA Ser83Leu,
ParC Ser80Arg
pBK-QnrA1 I 2 2 2 8 4 4 4 64
ATCC-S83L-S80R/qnrB GyrA Ser83Leu,
ParC Ser80Arg
pBK-QnrB1 S 1 1 1 4 2 1 2 4
ATCC-S83L-S80R/qnrS GyrA Ser83Leu,
ParC Ser80Arg
pBK-QnrS1 I 2 4 2 8 4 4 4 16
a PMQR, plasmid-mediated quinolone resistance.
b S and I, susceptible and intermediate susceptibility, respectively, according to CLSI guidelines (2).
c MICs determined by microdilution for ciprofloxacin (CIP), levofloxacin (LVX), moxifloxacin (MXF), and norfloxacin (NFX).
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duction in viable bacteria after 8 h of incubation. After 6 h, no
viable bacteria were recovered for the wild-type E. coli ATCC
25922 strain without qnr genes, while E. coli ATCC 25922 with
qnr gene expression maintained levels of 102 to 103 CFU/ml for
up to 24 h. At 4 the MIC of CIP, all qnr gene expression in
wild-type E. coli ATCC 25922 maintained a viable CFU/ml at
least 100-fold higher at 24 h compared to empty wild-type
strains (data not shown). CIP at 1 g/ml in the isogenic E. coli
ATCC-Ser83Leu strain (with and without qnr gene expression
[Fig. 1B]), caused a marked reduction in viable bacteria during
the first 8 h, except for strains expressing qnrS1. After 8 h,
bacterial regrowth was noted for strains expressing qnrA1,
qnrB1, and qnrS1, and this continued up to 24 h, although not
for E. coli ATCC-Ser83Leu, demonstrating the impact of qnr
genes in terms of bacterial viability.
Finally, we evaluated 16 isogenic E. coli strains harboring
different QRDR modifications, and with and without qnr-ex-
pressing genes such as qnrA1, qnrB1, and qnrS1. This study
showed that these mechanisms, implicated in low-level plas-
mid-mediated FQ resistance, may play a significant role in the
TABLE 2. Oligonucleotides and plasmids used in this study
Primer or plasmid Sequencea Use in this study Source orreference
qnr cloning
Pre-QnrA1 5-CGGGATCCCGCGGCAGTTAAAATTGGGGCT-3 Cloning of qnrA1 This study
Post-QnrA1 5-CGGGATCCCGACGCCGAGTCCCGACCAGACTGC-3 Cloning of qnrA1 This study
Pre-QnrB1 5-CGGGATCCCGCTTGGTCGCCCTGGCCAACC-3 Cloning of qnrB1 This study
Post-QnrB1 5-CGGGATCCCGGCAAACCAGCTTACAGCAGGC-3 Cloning of qnrB1 This study
Pre-QnrS1 5-CGGGATCCCGCCACTTAAAACAGGTAAATTG-3 Cloning of qnrS1 This study
Post-QnrS1 5-CGGGATCCCGTACATGGTTGTCCCTATGTC-3 Cloning of qnrS1 This study
Gene replacement
gyrAS83L-Fw 5-CCATGGTGACCTGGCGGTCTATG-3 Mutagenesis of gyrA This study
gyrAS83L-Rv 5-CATAGACCGCCAGGTCACCATGG-3 Mutagenesis of gyrA This study
parCS80R-Fw 5-CCGCACGGCGATCGCGCCTGTTATGAAGC-3 Mutagenesis of parC This study
parCS80R-Rv 5-GCTTCATAACAGGCGCGATCGCCGTGCGG-3 Mutagenesis of parC This study
Pre-gyrAS83 5-CGGGATCCCGAGCGATCTCTTCGTGGTCTACG-3 Partial gyrA amplification This study
Post-gyrAS83 5-CGGGATCCCGCCTGATACGGAATTTCGTGGAC-3 Partial gyrA amplification This study
Pre-parCS80 5-CGGGATCCCGGACCGCGATAGCGTTGTCTTCCG-3 Partial parC amplification This study
Post-parCS80 5-CGGGATCCCGCAGATCGGTGGTAGCGAAGAGGTG-3 Partial parC amplification This study
QRDRb sequencing
gyrA-1 5-AAATCTGCCCGTGTCGTTGGT-3 Sequencing 17
gyrA-2 5-GCCATACCTACGGCGATACC-3 Sequencing 17
parC-A 5-CTGAATGCCAGCGCCAAATT-3 Sequencing 17
parC-B 5-GCGAACGATTTCGGATCGTC-3 Sequencing 17
Plasmids
pBK-CMV Cloning vector
pST76C Gene replacement/suicide vector
pUC19RP12 Gene replacement/resolution vector
a Underlined nucleotides correspond to the BamHI site used for cloning.
b QRDR, quinolone resistance-determining region.
TABLE 3. Fluoroquinolone MPC, MSW, MPC time window, and MIC or MIC range for mutants of the eight isogenic strains
used in this study
E. coli strain/
plasmid gene
MPC (g/ml)a MSWb (MPC/MIC g/ml) MPC time window (h)c MIC or MIC range formutant (g/ml)d
CIP LVX MXF NFX CIP LVX MXF NFX CIP LVX MXF NFX CIP LVX MXF NFX
ATCC 25922 1 2 2 4 500 250 250 266.7 48 48 48 48 0.06 0.125 0.06 0.25
ATCC/qnrA 8 8 8 8 64 16 32 16 48 24 24 24 0.5 1–2 0.5–1 1–2
ATCC/qnrB 2 4 4 8 16 32 16 32 72 48 24 48 0.125 0.5 0.5–1 0.5–1
ATCC/qnrS 4 4 4 8 32 8 8 16 24 24 24 24 0.5–1 1–2 0.5–1 1–2
ATCC 25922-S83L 4 4 4 8 32 32 66.7 32 24 24 24 24 0.5 2 1 2
ATCC-S83L/qnrA 16 32 16 16 32 64 64 16 24 24 24 24 1–4 2–4 2–4 8–16
ATCC-S83L/qnrB 8 16 32 16 16 64 64 16 24 72 24 24 1–2 1–4 1–4 2–16
ATCC-S83L/qnrS 8 16 32 32 8 16 32 16 24 96 24 24 1–2 4 1–2 2–16
a MPC values were determined on Mueller-Hinton plates for ciprofloxacin (CIP), levofloxacin (LVX), moxifloxacin (MXF), and norfloxacin (NFX); MPC was defined
as the lowest antibiotic concentration (in the range of concentration steps analyzed) at which resistant colonies do not form.
b MSW, mutant selection window (i.e., the antibiotic concentration found between the MIC and MPC).
c Earliest time (in hours) at which resistant colonies were visible one step below the MPC.
d MICs for resistant colonies were recovered on Mueller-Hinton plates one step below the MPC value.
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acquisition of clinical resistance to FQ and, therefore, thera-
peutic failure. Animal models are necessary to confirm these in
vitro results.
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FIG. 1. Viable bacterial counts in time-kill curve assays with cipro-
floxacin (CIP) 1 g/ml. (A) Isogenic wild-type E. coli ATCC 25922,
with and without qnrA1, qnrB1, or qnrS1 gene expression; (B) isogenic
mutant E. coli ATCC 25922-S83L, with and without qnrA1, qnrB1, or
qnrS1 gene expression.
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